Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ES002023 |
| Synonyms | |
| Therapy Description |
ES002023 is a monoclonal antibody targeting ENTPD1 (CD39), which potentially induces an anti-tumor immune response (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ES002023 | ES-002023|ES 002023 | CD39 Antibody 5 | ES002023 is a monoclonal antibody targeting ENTPD1 (CD39), which potentially induces an anti-tumor immune response (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05075564 | Phase I | ES002023 | A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | 0 |